Search
Minerva Neurosciences Inc
NERVAdd to Watchlist
5.100USD
-0.050-0.97%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
223.59MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-0.97%
5 Days
+16.70%
1 Month
+6.69%
6 Months
+30.10%
Year to Date
+26.87%
1 Year
+209.09%
Key Figures
5.180Open
5.360High
286.90KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.65%Turnover Ratio
5.150Prev. Close
4.730Low
959.66KTurnover
155.40P/E Static
-0.88P/B
0.00%Div Yield TTM
-654.56%ROA
12.46052wk High
0.50Volume Ratio
1.44MNet Profit
43.84MShares
-37.0296EPS TTM
-0.17Beta
--ROE
1.48052wk Low
12.23%Amplitude
--Gross Margin
223.59MMarket Cap
1.37Reward/Risk
5.66%Risk Rate
TradingKey Stock Score of Minerva Neurosciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Minerva Neurosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 117 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 9.50.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Minerva Neurosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Minerva Neurosciences Inc Highlights
StrengthsRisks
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -0.14, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 31.80M shares, increasing 48.22% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
9.500
Target Price
+84.47%
Upside Space
Minerva Neurosciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Minerva Neurosciences Inc Info
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.
Ticker SymbolNERV
CompanyMinerva Neurosciences Inc
CEOLuthringer (Remy)
Websitehttps://www.minervaneurosciences.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Minerva Neurosciences Inc (NERV)?
The current price of Minerva Neurosciences Inc (NERV) is 5.10.
What is the symbol of Minerva Neurosciences Inc?
The ticker symbol of Minerva Neurosciences Inc is NERV.
What is the 52-week high of Minerva Neurosciences Inc?
The 52-week high of Minerva Neurosciences Inc is 12.46.
What is the 52-week low of Minerva Neurosciences Inc?
The 52-week low of Minerva Neurosciences Inc is 1.48.
What is the market capitalization of Minerva Neurosciences Inc?
The market capitalization of Minerva Neurosciences Inc is 223.59M.
Is Minerva Neurosciences Inc (NERV) currently rated as Buy, Hold, or Sell?
According to analysts, Minerva Neurosciences Inc (NERV) has an overall rating of signal_hold, with a price target of 9.50.
What is the Earnings Per Share (EPS TTM) of Minerva Neurosciences Inc (NERV)?
The Earnings Per Share (EPS TTM) of Minerva Neurosciences Inc (NERV) is -34.67.